Abstract | OBJECTIVES: METHODS: Patients with untreated RA (n=28), primary Sjogren's syndrome (pSS) ( n=30), and healthy controls (HCs) ( n=30) were enrolled for the screening assay. A total of 1128 serum proteins were analyzed using the SOMAscan™ assay. Serum levels of MMP-3 and interleukin (IL)-16 were measured using a latex turbidimetric immunoassay and ELISA at baseline and 12weeks after treatment with methotrexate (MTX) for MTX-naïve RA patients (n=28) or with the biologics tocilizumab (TCZ) (n=7), abatacept (ABT) (n=11) or infliximab (n=22) for MTX-inadequate response (IR) RA patients. Correlation analysis was conducted using Spearman's rank correlation method. RESULTS: Proteomics showed that serum IL-16 levels were most positively correlated with those of MMP-3 (ρ=0.51, p<0.01) and were significantly increased in patients with untreated active RA compared to HCs (p<0.01) or those with pSS (p<0.01). IL-16 levels decreased following treatment in both the MTX-naïve and MTX-IR groups. Regarding clinical response, fluctuations in IL-16 levels were positively associated with changes in clinical indicators, particularly the Clinical Disease Activity Index (ρ=0.89, p<0.01) in the TCZ and ABT-treated group. However, no similar correlation was noted in MMP-3 and acute phase reactants in any groups. CONCLUSIONS:
IL-16 was a more effective clinical parameter than MMP-3, C-reactive protein, or erythrocyte sedimentation rate in both MTX-naive and MTX-IR RA patients. IL-16 might be a useful biomarker for evaluating clinical response in RA patients.
|
Authors | Atsuko Murota, Katsuya Suzuki, Yoshiaki Kassai, Takahiro Miyazaki, Rimpei Morita, Yasushi Kondo, Masaru Takeshita, Yasuo Niki, Akihiko Yoshimura, Tsutomu Takeuchi |
Journal | Cytokine
(Cytokine)
Vol. 78
Pg. 87-93
(Feb 2016)
ISSN: 1096-0023 [Electronic] England |
PMID | 26700586
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Biomarkers
- Blood Proteins
- Interleukin-16
- Abatacept
- Infliximab
- MMP3 protein, human
- Matrix Metalloproteinase 3
- tocilizumab
- Methotrexate
|
Topics |
- Abatacept
(therapeutic use)
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(blood, drug therapy)
- Biomarkers
(blood)
- Blood Proteins
(analysis, immunology)
- Blood Sedimentation
- Female
- Humans
- Infliximab
(therapeutic use)
- Interleukin-16
(blood)
- Male
- Matrix Metalloproteinase 3
(blood)
- Methotrexate
(therapeutic use)
- Middle Aged
- Proteomics
- Statistics as Topic
- Treatment Outcome
|